

Subject Index

a

- A549 cell lines 26
- A549-pulmonary type II 115
- absorption, distribution, metabolism
and elimination (ADME) 15,
108, 275
- acellularization 10
- acute cytotoxicity 116
- acute oral toxicity 106
- adenoviral vectored HIV vaccines
166
- adenoviral vectors 156
- adenovirus type 5 182
- adenoviruses 156, 181
 - E1 region 181
 - E1B 19k 181
 - E1B 55k 181
- adherent cells 57
- ADME *see* absorption, distribution,
metabolism and elimination
- ADME-testing 275
- adult stem cells 18, 215
- aerosols 105
- agonistic activities 134
- AIDS 158, 190 ff.
- air pollution 115
- airborne contaminants 103 ff.
 - dust 104
 - fiber 104
 - fog 104
 - fume 104
 - gas 104
 - inhalation 103
 - mist 104
 - smoke 104
 - toxicology 106 ff.
 - vapor 104
- airborne formaldehyde 112
- air-liquid interface 114
- alginate 4 ff., 13
- alphaviruses 156
- alternative methods 244
- ALVAC-HIV vaccines 165
- alveolar tissue models 22 ff.
- alveolar type I and type II cells 22
- alveoli 23
- ALX 40-4C 191, 194
- Ames' test 256
- animal models 115
- animal studies 191, 255
- animal test replacement 263
- animal testing 205, 208
 - Alzheimer's disease 205
 - amyotrophic lateral sclerosis (ALS)
205
 - autoimmune encephalomyelitis
205
 - cancer 205
 - multiple sclerosis (MS) 208
 - neurodegeneration 205
- animal toxicology studies 106
- antibody maturation 69
- antigen presentation 156
- antigen-presenting cells (APC) 66,
160 ff.
- antiviral drug screening 189
- APC *see* antigen-presenting cells

- apoptosis 145, 181
 - activation 145
 - caspase-3 145
 - mitochondrial membrane potential 145
 - nuclear condensation 145
- ARF 181
- arrest M_0 181
- artificial blood vessels 62 ff.
- artificial immune system 65 ff.
- artificial lymph model 66
- artificial organoids 168
- assay quality 134 f.
- astrocyte attachment 37
- astrocytic cell lines 33 ff.
- astrocytic projections 32 ff.
- astrocytes 28 ff.
- atmospheric aerosols 112
- automated fluorescence microscopy 146
- avian influenza virus 27

- b**
- bacteriophage T7 promoter 194
- BAL *see* bioartificial liver
- basal lamina 26
- batch consistency 156
- batch process 59 ff.
- BBB *see* blood–brain barrier
- B-cell activation 68
- B-cell vaccination 158
- Bcl2 181
- BfR *see* Federal Institute for Risk Assessment
- bioadhesiveness 20
- bioartificial liver (BAL) 15 ff.
- bioassays 116
- bioavailability 221
- biochips 81 ff.
- biocompatibility 12
- biocompatible materials 82
- biodegradability 4 ff., 20
- biohazards 234
- biohybrid system 88
- biohybrid technology 80
- bioimpedance 86
 - spectroscopy 81
- bioinformatics 220
- biological endpoints 109
 - cell adhesion 109
 - cell metabolism 109
 - cell morphology 109
 - cell proliferation 109
 - cell viability 109
 - membrane leakage 109
- biological pharmaceuticals 54
- biologics 271
- biomarker signatures 208 ff.
- biomechanical factors 63
- bioreactors 19, 55, 57 ff., 59, 63, 69, 273, 277
 - circulation loop 57
 - control strategies 59
 - design 55 ff.
 - disposable 70
 - drug screening 69
 - fixed-bed 57
 - fluidized-bed 57
 - high aspect ratio vessel 19
 - microcarrier cultures 55
 - multipurpose 59
 - organ support devices 19
 - oxygen supply 63
 - parameters 277
 - process strategies 59
 - rotating wall vessel 19, 59
 - slow-turning lateral vessel 19
 - tissue penetration depth 63
- biosensor 142 f.
 - arrays 96
- biotransformation 110
- blastocytes 215
- blood oxygenation 105
- blood vessels, acellularized 10
- blood–brain barrier (BBB) 28 ff.
 - co-cultures 35
 - extracellular matrix 29
 - hemodynamic forces 38 ff.
 - human *in-vitro* models 37
 - hypertension 38

- impedance spectroscopy 89
- monocultures 35
- neurovascular physiological unit 28
- permeability 32
- pharmacological models 37
- porcine models 37
- shear stress 38
- three-cell type 35
- brain parenchyma 32
- brefeldin A 162
- bronchial tissue 22
- bubbling test 112

- c**
- Ca-chelators 138
- Caco-2 179
- Ca-imaging 218
- CAMP 138
- canarypox 155
- capillaries 274
- cardiac myocytes 17 ff.
- cardiac tissue engineering 16 ff.
- cardiac tissue repair 17
- cardiac valve engineering 20
- cardiomyocyte-based sensor 94 ff.
- cardiomyocytes 94
- CAT reporter genes 192
- CCA *see* cytokine capture assay
- CCR5 receptors 193
- CD107a 164
- CD4 receptors 193 f.
- CD4⁺ T-cells 158
- CDKN2A 181
- cell banks 241
 - ATCC 232
 - cell cultural collection 232
 - Coriell Institute 232
 - DSMZ 232
 - ECACC 232
 - ICLC 232
 - JCRB 232
 - quality control regimes 241
 - validation 232
- cell-based assays 239, 243, 281 ff.
 - bioelectronic 81
 - guidelines for validation 243
 - light-emitting 81
 - quality 239
 - reproducibility 239
- cell-based biosensors 80
- cell-based sensors 88 ff.
- cell-based therapy 53
- cell culture 237
 - conditions 237
 - differentiation state 237
 - identity 237
 - validity 237
 - vitality 237
- cell culture device 273
- cell culture models 259
- cell culture system 277
 - design of 277
 - parameters 277
 - process development 277
- cell cycle control 181
 - ARF 181
 - arrest M₀ 181
 - CDKN2A 181
 - E2F transcription factor 181
 - phosphorylation of Rb 181
 - progression 181 G₁ 181
 - p53-pathway 181
 - P16 INK4a 181
 - Rb-pathway 181
- cell density 131 f.
- cell expansion 55
- cell lines 115, 129 f., 133, 146, 155, 179, 182, 188
 - A549-pulmonary type II 115
 - authenticity 232 ff.
 - baby hamster kidney (BHK) 130
 - Caco-2 cells 133, 179
 - chinese hamster ovary (CHO) 130, 188
 - COS cells 130
 - cross-contamination 232 ff.
 - hepatoma BC2 179
 - hamster kidney 188

- hazards 243
- HEK293 130, 182
- HeLa cells 146, 155, 192, 240
- HepG2 179
- HepG2-hepatoma 115
- HK-2 184
- human 232
- Jurkat 192
- microbial contamination 238
- NIH-3T3 cells 130
- Ntera2 179
- quality control regimes 240
- recombinant 129
- stable target-expressing 129
- 3T3 188
- 3T3-L1 adipocytes 133
- u937 cells 146
- validation 232
- Vero cells 240
- cell storage 133
- cellular assays 146, 192
 - fetal bovine serum 192
 - human serum 192
- cellular autofluorescence 141
- cellular bioinformatics 147
- cellular dielectric spectroscopy 85
- cellular fusion assay 191
- cellular immune mechanisms 158 ff.
- cellular network 68
- cellular resistance 88 ff.
- cellular screening assays 134 ff.
- cellular target 137
- centrosome cycle 184
- cerebral microvascular endothelium 28 ff.
- cerebral milieu 32
- channelopathies 91
- cheer stress 19
- chemical diversity 210
- chicken embryo fibroblasts 155
- chicken HS4 insulator 186
- chitosan 13
- chromosomal abnormality 239
- chronic toxicity 244
- chronotropic compounds 94
- CMV *see* cytomegalovirus
- coatings 82
 - attractant 82
 - repellent 82
- co-expression 185
- COLIPA *see* European Cosmetics, Toiletry and Perfumery Association
- collagen 4 ff., 13
- colon 274
- conductive polymers 5
 - polyacetylene 5
 - polyaniline (PANi) 5
 - poly(para-phenylene vinylene) 5
 - polypyrrole (PPy) 5
 - polythiophene 5
- conductivity 20
- Contergan 215
- continuous cultivation 59
- control materials 232
- CPCRs *see* protein-coupled receptors
- Cre 186
- Cre/loxP 184
- CTL response 159
- CTL *see* cytotoxic CD8₊ T-lymphocytes
- culture media 131
- culture systems 57 ff.
- cyclin-dependent kinases 181 ff.
- cyncitia formation 194
- cystic fibrosis 27
- cytochrome P-450 15, 178, 256
- cytokine capture assay (CCA) 162 ff.
- cytokine secretion 162
- cytomegalovirus (CMV) 160
- cytopathic effect 189, 193
- cytotoxic CD8₊ T-lymphocytes (CTL) 158 ff., 163 f.
 - chromium release assay 163
 - flow cytometric assay 164
 - Lysispot assay 163
- cytotoxicity 163
 - assays 112
 - testing 107

d

3D *in-vitro* models 26
 3D *in-vitro* tissues 88
 3D microenvironment 54
 3D tissue cultures 63
 DCs *see* dendritic cells
 deacetylation of histones 186
 dedifferentiation 57
 dendritic cells (DCs) 66
 dengue virus 155
 designed host cells 190
 designed-cell-based systems 191
 designer cell lines 183, 188
 – avian 188
 – human 188
 designer cells 185 f.
 detoxification 11
 developmental restriction 215
 developmental toxicity 208
 diabetic patients 264
 dielectric behavior 85 ff.
 differentiation 215, 237, 273
 diffusion chamber system 115
 diffusion gradients 18
 dihydropyrimidinase-related
 protein 2 (DRP-2) 221
 dispersions (α , β , γ) 85
 distal airways 21
 divisional asymmetry 273 ff.
 DNA methylation 186
 DNA repair control 184
 DNA replicons 156
 donated human tissue 233 ff.
 Draize eye test 257
 DRP-2 *see* dihydropyrimidinase-
 related protein 2
 drug development 264, 271, 275
 drug discovery 88, 107, 127, 136,
 142, 177, 275
 drug-induced arrays 96
 drug-metabolizing systems 255
 drug screening conferences 96, 184,
 281
 drug targets 143, 144 ff.
 – CPCRs 143

– kinases 143
 – primary human cells 144
 drug testing conferences 281
 dynamic range 135

e

E2F transcription factor 181
 EBV *see* Epstein-Barr virus
 ECIS *see* electric cell-substrate
 impedance sensing
 ECM *see* extracellular matrix
 ectoderm germ layers 215
 ECVAM *see* European Centre for the
 Validation of Lateral Methods
 edge effect 132
 efficacy 153, 218
 elastin 4 ff.
 electric cell-substrate impedance
 sensing (ECIS) 86
 – apoptosis 86
 – barrier function 86
 – cell attachment 86
 – cell-substrate interaction 86
 – chemotaxis 86
 – sensitivity 87
 – signal transduction 86
 electrical resistance 28
 electrogenic cells 93
 electrospinning 7 ff.
 embryoid bodies 215
 embryonal environment 277
 embryonic stem cells (ESC) 18,
 146, 179, 206, 278
 – differentiations 208
 – human 206
 – murine 206
 embryonic tissue 182
 embryotoxicity 215, 217 ff., 244
 EMEA *see* European Agency for the
 Evaluation of Medical Products
 emphysema 27
 endocrine disruptors 214
 endocrine homeostasis 214
 endoderm germ layers 215
 endothelial cell lines 33 ff.

- transendothelial electrical resistance 33
- endothelial cells 18, 87, 180
- endothelial differentiation 182
- endothelial junctions 28
- endpoints 259
- environmental asymmetry 273 ff.
- enzyme-linked immunospot assay 160
 - IFN- γ 160
- epigenetic events 219
- epigenomic phenomena 188
- epithelial cell lines 26
- Epstein-Barr virus (EBV) 160
- ESC *see* embryonic stem cells
- European Agency for the Evaluation of Medical Products (EMA) 97
- European Centre for the Validation of Alternative Methods (ECVAM) 110, 208, 232, 244, 251
- European Cosmetics, Toiletry and Perfumery Association (COLIPA)
- European Network of Research Tissue Banks 235
- European Pharmacopoeia 244
- expansion *in-vitro* 278
- experimental animal numbers 256 f.
- experimental animals 252 ff.
 - developing alternatives 252
 - EU Directive 86/EEC 252
 - legal framework 252
- exposure 106
 - long-term repeated studies 106
 - short-term studies 106
 - single 106
- exposure chambers 115
- exposure technique 111
 - direct methods 111 ff.
 - indirect methods 111 ff.
- expression level 188
- extracellular matrix (ECM) 3, 6, 22
- extracorporeal liver device 57

f

- FDA *see* Food and Drug Administration
- Administration
- fed-batch process 59 ff.
- Federal Institute for Risk Assessment (BfR) 208
- fibroblasts 18, 190
- fibrosarcoma QT6-C5 194
- Flp 186
- Flp/RT 184
- fluorophores 141
 - fixation procedures 141
 - fluorescent semiconductor nanocrystals 141
 - GFP 141
 - long-wavelength dyes 141
 - multicolor assays 141
 - photostability 141
 - resistance 141
 - solubility 141
- follicular dendritic cell networks 167
- Food and Drug Administration (FDA) 96, 271
- fowlpox 155
- fort sites 187 ff.
- functional screens 128 ff.

g

- gap junctions 145
- gas exchange 105
- gaseous contaminants 113
- genetic stability 239
- genomic locus 186 ff.
- genomics 209
- genotoxicity 107
- genotypic diversity 278
- germ layers 215 f.
 - ectoderm 215
 - endoderm 215
 - mesoderm 215
- germinal centers 69, 167
- GFP *see* green fluorescence protein
- giga seal formation 92
- glomerular epithelial cells 184
- GMP *see* good manufacturing practice

- good cell culture practice 233
 good manufacturing practice (GMP) 264
 good quality tissues for testing 236
 G-protein coupled receptors (GPCRs) 88, 142 f.
 – internalization assays 142
 – pharmacological characterization 142
 – receptor-tagged dye 143
 – signaling pathways 143
 – translocation 142
 G-protein receptors 137
 granzyme B 164
 green fluorescence protein (GFP) 141
 growth rate 238
 growth receptor pathways 137
 growth-arrested cells 133
 guidelines for validation 243 ff.
- h**
- HAART *see* highly active anti-retroviral therapy
 HBV *see* hepatitis B virus
 hCMV promoter 186
 HCS *see* high-content screening
 HCV *see* hepatitis C virus
 heart 91
 – muscle 17
 – valves 20
 heart tissue 17, 88
 – acellularized 10
 – electrical activities 17
 – hypertrophy 17
 – mechanical function 17
 HEK293 182
 HeLa cell line 155, 240
 HeLa cells 193
 hematopoietic stem cells 68, 180, 275
 hepatic drug discovery 15
 hepatic spheroids 15
 hepatitis B virus (HBV) 191
 hepatitis B virus vaccine 153
 hepatitis C virus (HCV) 191
 hepatocytes 11 ff., 113, 178, 184, 255
 hepatoma BC2 179
 HepG2 179
 HepG2-hepatoma 115
 heterologous antigens 157
 high-content screening (HCS) 79, 142
 – CPCRs 142
 – mechanism-oriented 142
 – multiplexed assay 144
 – primary human cells 144
 – target oriented 142
 high-resolution images 139
 high-throughput screening (HTS) 62, 79, 92, 127, 130, 133, 139, 184, 192, 213, 277
 – amount of cells 132 f.
 – assay interference 135
 – automation systems 133
 – cAMP 138
 – cell storage 133
 – ELISA-based assays 134 f.
 – fluorescence imaging 138
 – fluorescent probes 140 ff.
 – instrumentation 139
 – intracellular Ca²⁺ 138
 – ion channels 138
 – reader characteristics 140
 – second messenger assays 138
 – target-unrelated effects 135
 highly active anti-retroviral therapy (HAART) 190
 Hinxton Statement 233
 histone acetylase 182
 HIV-vaccines 166 ff.
 HIV-1 *see* human immunodeficiency virus type 1
 HIV-1 vaccines 166
 HK-2 184
 H5N1 replication 27
 hollow-fiber bioreactors 15, 38, 273
 homeostatic conditions 237, 273
 homologous recombination 186 ff.
 host cells 189
 housekeeping genes 186

- HPV E6 182
 HTLV-I virus 189
 HTS *see* high throughput screening
 HUH-7 cells 196
 human cell lines 232
 human cell supply 278
 human cells, hazards 242
 human embryonal stem cells 207, 217
 – enzyme activities 217
 – ethical concerns 221
 – surface antigens 217
 – undifferentiated 217
 human environment 273
 human genome project 209
 human histotypic cultures 273
 human immunodeficiency 189, 193 f.
 – abacavir 193
 – AZT 193
 – enfuvirtide 193
 – T-20 193
 – 3TC 193
 – zidovudine 193
 human immunodeficiency virus
 type 1 (HIV-1) 154 ff., 158
 – acute viremia phase 158
 – Ad5 viral vector 159
 – clinical trials 165 ff.
 – CTL response 159
 – efficacy 161
 – glycoprotein gp120 158
 – p24 161
 – potency 161
 – recombinant poxvirus vaccines 159
 – seronegatives 158
 – therapeutic vaccine 159
 – viral clearance 159
 human *in-vitro* models 37
 human papillomavirus 181
 human placental model 57
 human stem cell sources 279
 human stem cells 273
 human telomerase 180
 human tissues 233 ff.
 – approval 233
 – availability 233
 – hazards 242
 – informed consent 233
 – recommendations 234
 hyaluronic hydrogels 36
- i**
- ICCVAM *see* Interagency
 Coordinating Center for the
 Validation of Alternative Methods
 ICH *see* International Conference on
 Harmonisation
 ICS *see* intracellular cytokine staining
 IFN- γ ELISPOT 160 ff.
 immobile cell phase 57
 immortal cell lines 184
 immortalization 179 ff., 183 f., 233
 – conditional 183
 immune cell therapies 65
 immune cells 178
 immune functions 65 ff., 168
 immune organs 65
 – primary 65
 – secondary 65
 immune response 68
 – cellular 68
 – humoral 68
 immunity 153
 – pre-existing 157
 immunization 167
 immunoassays 153, 158
 immunogenicity 54 ff., 156
 – testing 275
 immunological synapses 68
 immunotoxicity 54 ff.
 impedance 88, 90
 – frequency-dependent 90
 – recording platform 88
 – spectroscopy 85 ff.
 inflammatory cell systems 146
 influenza virus 155
 inhalation 109
 inhalation toxicity 107

- acute 107
 - repeated dose 107
 - subchronic 107
 - inhibitors of transactivation 193
 - in-silico* membrane permeation assay 39
 - insulin 264
 - integration locus 188
 - intelligent biomatrices 3 ff.
 - intelligent biomimetic scaffolds 3 ff.
 - Interagency Coordinating Center for the Validation of Alternative Methods (ICCVAM) 251
 - International Conference on Harmonisation (ICH) 214
 - intracellular Ca²⁺ 138
 - intracellular cytokine staining (ICS) 160, 162 ff.
 - intracellular fluorophore labeling 142
 - biarsenical fluorophores 142
 - O⁶-alkylguanine-DNA alkyltransferase 142
 - intracellular trafficking 143
 - intranasal administration 167
 - in-vitro* assay 191
 - in-vitro* culture 272 ff.
 - history 272
 - in-vitro* drug screens 195
 - in-vitro* exposure 111
 - in-vitro* exposure system 115
 - in-vitro* gas exposure 113
 - in-vitro* inhalation studies 115
 - in-vitro* method 263
 - biological drugs 263
 - in-vitro* models 108, 178, 210, 221, 259
 - for organ toxicity 108
 - hematotoxic 108
 - hESC-based 217
 - nephrotoxic 108
 - neurotoxic 108
 - in-vitro* phototoxicity test 252
 - in-vitro* testing 15, 154 ff.
 - relevance 154
 - validity 154
 - in-vitro* tests 259
 - in-vitro* tissue models 15
 - in-vitro* toxicity 258
 - in-vitro* toxicology 107 ff.
 - cytotoxicity testing 107
 - irritancy testing 107
 - mutagenicity 107
 - organ toxicity 107
 - reproductive toxicity 107
 - in-vivo* environments 273
 - in-vivo* situation 238
 - in-vivo* tests 213
 - ion channels 91, 138, 219
 - channelopathies 91
 - central nervous system 91
 - heart 91
 - hereditary diseases 92
 - ionotropic receptors 218
- j**
- JaCVAM *see* Japanese Centre for Evaluation of Alternative Methods
 - Japanese Centre for Evaluation of Alternative Methods (JaCVAM) 244, 252
 - Japanese encephalitis virus 155
 - Jurkat cell lines 192
- k**
- keratinocytes 180
 - kidney 184, 274
 - kinases 143
 - autophosphorylation 143
 - kinetic measurements 139
- l**
- lacZ 194
 - reporter genes 192
 - lead optimization 127, 143
 - legal guidelines 218
 - leukemia inhibitory factor (LIF) 215
 - LIF *see* leukemia inhibitory factor

- lipid bilayers 91, 194
 - lipid film 91
 - lipid rafts 90
 - Lipobay 215
 - lipophilicity 29
 - live cell imaging 145
 - live cell measurements 139
 - LiveCount assay 164
 - liver 11 ff.
 - animal models 15
 - failure 15
 - metabolism 11, 15
 - scaffolds 12 ff.
 - slices 178
 - tissue engineering 11
 - local microenvironment 68
 - LTR-reporter system 190
 - luciferase expression cassette 194
 - lung 21 ff., 274
 - acellularized 10
 - distal airways 21
 - extracellular matrix 22
 - Matrigel 22
 - pharmacological models 27
 - proximal airways 21
 - tissue engineering 21 ff.
 - lymph node 274
 - lymphatic cells 65
 - lymphatic fluid 66
 - lymphocyte segregation 69
 - lymphocytes 66
 - lymphoid organs 167
 - lymphoid tissue 65
 - lyophilization 9
- m**
- mass transfer 56 ff.
 - resistance 63
 - Master Cell Bank 129, 241
 - matrigel 5, 9, 20, 22
 - matrix deposition 59
 - mean deviation 135
 - measles virus 155
 - mechanical strength 19
 - membrane potential 138
 - membrane transistors 90 ff.
 - MEMS *see* microelectrochemical systems
 - mesenchymal stem cells 180
 - mesoderm germ layers 215
 - metabotropic receptors 218
 - microelectrode arrays 62
 - microelectrodes 94 ff.
 - microelectromechanical systems (MEMS) 16
 - microfluidic channel system 92 ff.
 - micro-organoids 275 ff., 278
 - assembly of 278
 - genotypic diversity 278
 - predisposition 278
 - microporous hollow fibres 67
 - microsystems technology 80, 81 ff.
 - microvascular endothelium 29
 - miniaturization 134
 - miniaturized cultur systems 178
 - mitochondrial membrane potential 146
 - chloromethyl-X-rosmaine 146
 - MMEAs multi-electrode assays
 - mobile cell phase 67
 - modified vaccinia virus Ankara (MVA) 155
 - molecular changes 210
 - molecular models 262
 - monensin 162
 - monolayer culture 57
 - multicellular spheroid model 62
 - multi-electrode assays (MMEAs) 81
 - multiparametric chips 82
 - multiparametric sensor chip 96 ff.
 - multicolor assays 141
 - murine embryonic stem cells 206
 - mutagenicity 107
 - mutation rates 190
 - MVA *see* modified vaccinia virus Ankara
 - MVA-vectores vaccines 165
 - myc 182
 - Mycoplasma* 238 ff.
 - testing 239

myelotoxicity 244
 myocardial infarction 17
 myocardium 17 ff.

n

nanotechnology 245
 natural biomaterials 4 ff.
 – alginate 4 ff.
 – collagen 4 ff.
 – elastin 4 ff.
neo gene 187
 neural tissues 88
 neuronal cells 18
 neuronal monolayer networks 95 ff.
 neuronal stem cells 180
 neurons 28 ff., 179, 217
 neuroprotective conditions 219
 neuroprotective substance 219
 neurospheres 88
 neurotoxic effects 217
 neurotoxicity 218
 neurotoxins 95
 neurovascular physiological entity
 28
 neutralizing antibodies 153, 158 ff.
 nitrogen dioxide 115
 nonenzymatic solutions 132
 Ntera2 179
 nuclear receptors 137

o

OECD *see* Organisation of Economic
 Cooperation and Development
 OECD-guidelines 258
 – harmonization 259
 – testing of chemicals 259
 oncogenes 180
 organ slice culture 62
 Organisation of Economic
 Cooperation and Development
 (OECD) 244
 organoids 65, 275, 278
 – genotypic diversity 278
 – *in-vitro* assembly of 278
 organotypic cell cultures 208

organotypic culture conditions 238
 osteocytes 184
 oxygen supply 56 ff., 63
 oxygenation 67
 ozone 112

p

P(LLA-CL) *see* poly(L-lactide-co-ε-
 caprolactone)
 P16 INK4a 181
 P53-pathway 181
 PACE *see* phosphospecific antibody
 cell-based ELISA
 pancreas 274
 PANi *see* polyaniline
 parainfluenza virus 155
 parasite plasmodium 190
 parasites 189
 patch-clamp technique 92 ff., 139
 PCL *see* poly(ε-caprolactone)
 percutaneous absorption 244
 perfusion 59, 66
 – bioreactors 68
 pericytes 28 ff., 36
 permeability 28
 – coefficient 34
 peroxisome proliferator-activated
 receptor 178
 persistent infection 190
 PET *see* polyethylene terephthalate
 filters
 PGA *see* polyglycolic acid
 pharmaceutical testing 92
 pharmacokinetic properties 15
 pharmacokinetics 221
 pharmacological models 27, 37
 pharmacologically active compounds
 146
 pharmacopoeia 252
 – standards 232
 phenotypic screening 139
 phosphorylation 143, 145
 – of Rb 181
 phosphospecific antibody cell-based
 ELISA (PACE) screens 136

- phototoxicity 244
 phototoxicity test 260 ff.
 – Annex V of Directive 67/548 EEC 261
 pituitary gland 274
 PLA *see* polylactic acid
 plasmid DNA vaccines 165
 plasticity 33
 PLGA *see* poly(lactidic-co-glycolic acid)
 pluripotent stem cells 273
 polio vaccine 155
 poly(ϵ -caprolactone (PCL)) 4 ff.
 poly(lactidic-co-glycolic acid) (PLGA) 4 ff., 13
 poly(L-lactide-co- ϵ -caprolactone) (P(LLA-CL)) 4 ff., 13
 polyaniline (PANi) 5
 polyethylene terephthalate filters (PET) 34
 polyglycolic acid (PGA) 4 ff., 13
 polymerase II complex 182
 polypyrrole (Ppy) 5
 POT1 180
 potency 156
 – batch consistency 156
 poxvirus-based HIV vaccines 166
 poxviruses 155 ff.
 – avian 155
 Ppy *see* polypyrrole
 prediction model 259
 predisposition 278
 pregnancy 217
 preventive vaccines 167
 primary cells 178 ff.
 – limitations 178
 – suitability 178
 prime-boost regimes 165
 process flows 56
 – circulation 56
 – convection 56
 – perfusion 56
 – transfusion 56
 procyanidolic oligomers 36
 proliferation 215, 238
 – assays 128 ff.
 promoter 186 ff.
 protein biomarkers 210
 protein modifications 209
 – post-transcriptional 209
 – post-translational 209
 protein phosphatase 181
 protein-coupled receptors (CPCRs) 185
 proteomic display techniques 217
 proteomics 210 ff.
 – technologies 208
 provirus 190
 proximal airways 21
 pulmonary cells 26
 pulmonary tissue models 21 ff.
 pulmonary toxicology 27
 pyrogen testing 244
- q**
- QSARs *see* quantitative structure–activity relationships
 quality control 263
 – biological drugs 263
 quantitative structure–activity relationships (QSARs) 261
 quantum dots 141
- r**
- radiometric cellular assays 136 f.
 Ran GTPase 184
 rapid screening 139
 Rb-pathway 181
 REACH *see* Registration, Evaluation and Authorization of Chemicals
 reactogenicity 165
 real-time conditions 87
 receptor binding assays 136
 receptor tyrosine kinase (RTK) 143
 recombinant vectors 155
 recombination 187 ff.
 – cassette 187 ff.
 – consecutive 187
 recording techniques 93
 – cardiomyocytes 94
 – extracellular 93

- intracellular 93
 - redifferentiation 215
 - reference materials 244
 - reference standards 232
 - biological 232
 - international 232
 - Registration, Evaluation and Authorization of Chemicals (REACH) 205, 261
 - regulatory safety testing 257
 - reporter gene assays 137
 - reporter gene-based tests 214
 - reproducibility 132
 - reproductive toxicity 107
 - reproductive toxicology 213 ff.
 - reprogramming 219
 - respiratory diseases 22
 - respiratory infections 157
 - respiratory syncytial virus 155
 - respiratory system 105
 - respiratory tract 105
 - retinal pigment epithelial cells 180
 - retroviral gene transfer 186
 - retroviruses 190
 - risk assessment 234
 - risk-management 275
 - RNA replicons 156
 - RNA silencing (siRNA) 211 ff.
 - Ro 24-7429 191
 - roadside airborne particulates 112
 - robustness 135
 - 3Rs 231, 251
 - RTK *see* receptor tyrosine kinase
- s**
- safety 153
 - testing 252
 - toxicology 214
 - scaffold porosity 12 ff.
 - scaffolds 11 ff., 184
 - biodegradable 12 ff.
 - bioerodible 12 ff.
 - cell seeding 56
 - electrospun 8
 - scaffolds for tissue engineering 7 ff.
 - fabrication 7 ff.
 - solid 7
 - scintillation proximity 137
 - second messenger assays 138
 - selection marker 188
 - semiconductor 91
 - coupling electroactive proteins 91
 - membrane-based 91
 - Semliki Forest virus (SFV) 156
 - senescence 180
 - SFV *see* Semliki Forest virus
 - shuttle vector 186
 - signal shift 132
 - signal transduction pathways 137
 - signaling pathways 143
 - signaling proteins 143
 - silencing technologies 208
 - silicon nitride membranes 36 ff.
 - Sindbis virus (SINV) 156
 - single cell analysis 245
 - SINV *see* Sindbis virus
 - SiRNA *see* RNA silencing
 - siRNA *see* small interfering RNA
 - SIS *see* small intestinal submucosa
 - site-specific recombinases 186
 - Cre 186
 - Flp 186
 - skin 274
 - skin corrosivity 244
 - skin irritation test 261
 - skin sensitization 244
 - small interfering RNA (siRNA) 182
 - small intestinal submucosa (SIS) 5
 - small T antigen 181
 - smooth muscle cells 18
 - socio-ethical environment 280
 - SOD *see* superoxide dismutase
 - soft-lithography 82
 - solvent tolerance 131
 - somatic cells 180
 - somatic stem cell niches 277, 279
 - spermatogonial stem cells (SSC) 179
 - SSC *see* spermatogonial stem cells
 - standard 134

- blank control 134
 - positive control 134
 - standard deviation 135
 - standardization 232, 237 ff.
 - static culture conditions 18
 - stem cells 180, 278
 - adult 278
 - derived 278
 - differentiation 279
 - models 221
 - niches 273 ff.
 - prenatal 278
 - technologies 273
 - sterility testing 239
 - stroke models 205
 - submerged exposure technique 113
 - sub-organe structures 274
 - sub-organoid structures 275
 - substrate-integrated electrodes 93
 - superoxide dismutase (SOD) 221
 - surrogate biomarker 208 ff.
 - SV40 large T antigen 181 ff.
 - synthetic metals 4
 - synthetic organs 167
 - synthetic polymers 4 ff., 8
 - poly(ϵ -caprolactone) (PCL) 4 ff.
 - poly(L-lactide-co- ϵ -caprolactone (LLA-CL) 4 ff.
 - polyglycolic acid (PGA) 4 ff.
 - polylactic acid (PLA) 4
 - poly(lactidic-co-glycolic acid (PLGA) 4 ff.
 - systemic toxicology 213
 - systems biology 218 ff., 271, 281
- t**
- target oncology 144
 - target validation 80, 211
 - targets 127
 - Tat inhibitor 191
 - Ro 5-3335 191
 - Ro24-7429 191
 - Tat proteins 190
 - T cells 155, 191
 - antigen-specific 155
 - T-cell activation 68
 - T-cell assay 160
 - antigen-specific 160
 - enzyme-linked immunospot assay 160
 - intracellular cytokine staining 160
 - limiting dilution assay 160
 - T-cell cytotoxicity 163 f.
 - chromium release assay 163
 - flow cytometric assays 164
 - Lysispot assay 163 ff.
 - T-cell responses 153, 158, 165
 - telomerase 180 ff.
 - telomeres 180
 - temperatur-dependent inactivation 184
 - TER *see* transcellular electric resistance
 - tert gene 180
 - ectopic expression 180
 - endothelial cells 190
 - fibroblasts 180
 - keratinocytes 190
 - retinal pigment epithelial cells 180
 - TGF- β 36
 - thermoreversible gels 21
 - three-dimensional spheroids 146
 - thymic organoids 168
 - thyroid epithelium 184
 - tight junctions 28, 273
 - tissue banks 233 f.
 - tissue-based assays 243, 277
 - guidelines for validation 243 ff.
 - parameters 277
 - tissue-based impedimetric HTS 80
 - tissue-based sensor 88 ff.
 - tissue culture 237
 - conditions 237
 - differentiation state 237
 - identity 237
 - models 259
 - validity 237

- vitality 237
 - tissue engineering 16 ff., 21 ff., 36 ff., 53
 - tissue equivalents 3 ff.
 - tissue models 277
 - parameters 277
 - tissue-tracking system 234
 - toponome 80
 - toxic potency 110
 - toxicity endpoints 116
 - toxicity prediction 110
 - toxicity testing 205 ff.
 - toxicology 105 ff., 178
 - trans-activator 193
 - transcellular electric resistance (TER) 89
 - transcellular permeability 32
 - active 32
 - passive 32
 - transcriptase activity 180
 - transcription factor beta-catenin 145
 - transcription factors 186
 - transformation 179 ff.
 - transgenic animal models 211
 - transgenic mice 182
 - transient transfection 129 ff.
 - adenoviruses 130
 - calcium phosphate 130
 - PEI 130
 - Semliki Forest virus 130
 - transwell culture systems 34
 - transwell cultures 113 ff.
 - TRF1 180
 - TRF2 180
 - tumor cell lines 179
 - tumor spheroids 88
- v**
- vaccination schedules 165
 - vaccine efficacy 167
 - vaccine immunogenicity 167
 - vaccine testing 168
 - vaccines 153
 - adjuvant effects 153
 - complex 154
 - efficacy 153
 - hepatitis B virus 153
 - inactivated 154
 - live-attenuated 153
 - potency 154
 - preventive 153
 - prophylactic 153
 - recombinant viral vector 155
 - safety 153
 - therapeutic 154
 - viral 154
 - vaccinia virus 155 ff.
 - validated potency assays 155
 - validation 178, 211 ff., 220, 243 ff., 358 ff.
 - Amden workshop 258
 - cell culture models 259
 - guidelines 242
 - *in-vitro* models 259
 - *in-vitro* tests 259
 - photoirradiation test 260
 - phototoxicity test 260 ff.
 - studies 244
 - tissue culture models 259
 - variability 135
 - vector vaccine DNA 155
 - Venezuelan equine encephalitis virus (VEE) 156
 - Vero cells 240
 - vesicular stomatitis virus (VSV) 159
 - vimentin 182
 - viral isolates 192
 - viral promoters 185 ff.
 - immediate early hCMV 185
 - Rous sarcoma virus (RSV) 185
 - virus replication 155
 - virus-specific CTL 163
 - viruses 238 ff.
 - VOCs *see* volatile organic compounds
 - volatile compounds 113
 - volatile organic compounds (VOCs) 114
 - VSV *see* vesicular stomatitis virus

w

WCPF *see* whole cell fingerprinting system
whole cell fingerprinting system (WCPF) 80

z

Zentralstelle zur Erfassung und Bewertung von Ersatz- und Ergänzungsmethoden zum Tierversuch (ZEBET) 251
zidovudine 193